June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Treatment of bacterial and viral conjunctivitis with topical ultrapure stable hypochlorous acid (HOCl): a clinical evaluation and treatment response in 79 cases
Author Affiliations & Notes
  • Peter S Adamson
    ORBIT, UCL, Institute of Ophthalmology, London, United Kingdom
  • Hendrik Roos
    HPA-Scientific, Port Louis, Mauritius
  • Jon von Holdt
    Classique Optical, Johannesburg, South Africa
  • Footnotes
    Commercial Relationships Peter Adamson, HPA Scientific (I); Hendrik Roos, HPA-Scientific (I); Jon von Holdt, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 280. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter S Adamson, Hendrik Roos, Jon von Holdt; Treatment of bacterial and viral conjunctivitis with topical ultrapure stable hypochlorous acid (HOCl): a clinical evaluation and treatment response in 79 cases. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):280.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Determine the efficacy and tolerability of ultrapure stablised hypochlorous acid as a general anti-microbial agent in the treatment of bacterial and viral conjunctivitis. Hypochlorous acid is one of the most efficient anti-microbial agents, effective against numerous bacteria and viruses including MRSA and HIV, as well as fungi. Hypochlorous acid mediates its action on contact and is self-sterilising and with no possibility of emerging resistance. Previous methods of manufacture contain other chorine compounds, such as chlorine gas and hypochlorite which are noxious and irritating to the eye. We have developed an ultrapure and stabilized HOCl solution and have undertaken studies to determine the utility in treating infective eye disease.

Methods: 65 cases of bacterial and 14 cases of viral conjunctivitis (which included one case of severe viral corneal endothelitis) were treated with a solution of Ultrapure Stabilized HOCl at 80mg/l, pH 5.4. Tolerability and efficacy were noted during the treatment period. HOCl eye drops were administered two drops in each eye 3 times per day and prior to sleep. The clinical response and tolerability was examined at day 1, 3 and 7.

Results: Total resolution of the bacterial conjunctivitis occurred in 64/65 cases examined, including one subject who had previously failed Tobramax, Tobradex, Maxitrol and Fuse ointment. One bacterial case had a poor response, possibly due to compliance issues and the presence of a systemic infection. All viral conjunctivitis cases showed complete and rapid resolution of symptoms. In addition to resolution of the infection, all patents showed rapid improvement of redness, eye discharge, photophobia and impaired vision. In the one case with associated viral corneal endothelitis, corneal clouding resolved with normal vision returning. No tolerability issues were identified.

Conclusions: A new treatment method for infective eye conditions is proposed which does not rely on the use of topical antibiotics. HOCl, when applied at 80mg/l pH5.4, is profoundly effective and well tolerated in cases of bacterial or viral conjunctivitis.HOCl is cheap to manufacture and is stable at ambient temperatures and may be useful in the treatment of infective eye disease in locations where access to antibiotics is difficult.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.